MYO9A
Unconventional myosin-IXa
Also known as: FLJ11061, FLJ13244, MGC71859, MYO9A_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- B2RTY4
- Gene
- MYO9A
- Ensembl
- ENSG00000066933
- Chromosome
- 15
- Canonical length
- 2548 aa
- Protein class
- Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins
- Subcellular location
- Plasma membrane
OverviewNCBI Gene
This gene encodes a member of the myosin superfamily. The protein represents an unconventional myosin; it should not be confused with the conventional non-muscle myosin-9 (MYH9). Unconventional myosins contain the basic domains of conventional myosins and are further distinguished from class members by their tail domains. They function as actin-based molecular motors. Mutations in this gene have been associated with Bardet-Biedl Syndrome. [provided by RefSeq, Dec 2011]
Canonical amino-acid sequenceUniProt
2548 residues, UniProt reviewed canonical sequence.
>B2RTY4|MYO9A
1 MNINDGGRRR FEDNEHTLRI YPGAISEGTI YCPIPARKNS TAAEVIESLI NKLHLDKTKC
61 YVLAEVKEFG GEEWILNPTD CPVQRMMLWP RMALENRLSG EDYRFLLREK NLDGSIHYGS
121 LQSWLRVTEE RRRMMERGFL PQPQQKDFDD LCSLPDLNEK TLLENLRNRF KHEKIYTYVG
181 SILIVINPFK FLPIYNPKYV KMYDNHQLGK LEPHIYAVAD VAYHAMLQRK KNQCIVISGE
241 SGSGKTQSTN FLIHHLTALS QKGFASGVEQ IILGAGPVLE AFGNAKTAHN NNSSRFGKFI
301 QVNYQETGTV LGAYVEKYLL EKSRLVYQEH NERNYHVFYY LLAGASEDER SAFHLKQPEE
361 YHYLNQITKK PLRQSWDDYC YDSEPDCFTV EGEDLRHDFE RLQLAMEMVG FLPKTRRQIF
421 SLLSAILHLG NICYKKKTYR DDSIDICNPE VLPIVSELLE VKEEMLFEAL VTRKTVTVGE
481 KLILPYKLAE AVTVRNSMAK SLYSALFDWI VFRINHALLN SKDLEHNTKT LSIGVLDIFG
541 FEDYENNSFE QFCINFANER LQHYFNQHIF KLEQEEYRTE GISWHNIDYI DNTCCINLIS
601 KKPTGLLHLL DEESNFPQAT NQTLLDKFKH QHEDNSYIEF PAVMEPAFII KHYAGKVKYG
661 VKDFREKNTD HMRPDIVALL RSSKNAFISG MIGIDPVAVF RWAILRAFFR AMVAFREAGK
721 RNIHRKTGHD DTAPCAILKS MDSFSFLQHP VHQRSLEILQ RCKEEKYSIT RKNPRTPLSD
781 LQGMNALNEK NQHDTFDIAW NGRTGIRQSR LSSGTSLLDK DGIFANSTSS KLLERAHGIL
841 TRNKNFKSKP ALPKHLLEVN SLKHLTRLTL QDRITKSLLH LHKKKKPPSI SAQFQASLSK
901 LMETLGQAEP YFVKCIRSNA EKLPLRFSDV LVLRQLRYTG MLETVRIRQS GYSSKYSFQD
961 FVSHFHVLLP RNIIPSKFNI QDFFRKINLN PDNYQVGKTM VFLKEQERQH LQDLLHQEVL
1021 RRIILLQRWF RVLLCRQHFL HLRQASVIIQ RFWRNYLNQK QVRDAAVQKD AFVMASAAAL
1081 LQASWRAHLE RQRYLELRAA AIVIQQKWRD YYRRRHMAAI CIQARWKAYR ESKRYQEQRK
1141 KIILLQSTCR GFRARQRFKA LKEQRLRETK PEVGLVNIKG YGSLEIQGSD PSGWEDCSFD
1201 NRIKAIEECK SVIESNRISR ESSVDCLKES PNKQQERAQS QSGVDLQEDV LVRERPRSLE
1261 DLHQKKVGRA KRESRRMREL EQAIFSLELL KVRSLGGISP SEDRRWSTEL VPEGLQSPRG
1321 TPDSESSQGS LELLSYEESQ KSKLESVISD EGDLQFPSPK ISSSPKFDSR DNALSASNET
1381 SSAEHLKDGT MKEMVVCSSE SITCKPQLKD SFISNSLPTF FYIPQQDPLK TNSQLDTSIQ
1441 RNKLLENEDT AGEALTLDIN RETRRYHCSG KDQIVPSLNT ESSNPVLKKL EKLNTEKEER
1501 QKQLQQQNEK EMMEQIRQQT DILEKERKAF KTIEKPRIGE CLVAPSSYQS KQRVERPSSL
1561 LSLNTSNKGE LNVLGSLSLK DAALAQKDSS SAHLPPKDRP VTVFFERKGS PCQSSTVKEL
1621 SKTDRMGTQL NVACKLSNNR ISKREHFRPT QSYSHNSDDL SREGNARPIF FTPKDNMSIP
1681 LVSKEALNSK NPQLHKEDEP AWKPVKLAGP GQRETSQRFS SVDEQAKLHK TMSQGEITKL
1741 AVRQKASDSD IRPQRAKMRF WAKGKQGEKK TTRVKPTTQS EVSPLFAGTD VIPAHQFPDE
1801 LAAYHPTPPL SPELPGSCRK EFKENKEPSP KAKRKRSVKI SNVALDSMHW QNDSVQIIAS
1861 VSDLKSMDEF LLKKVNDLDN EDSKKDTLVD VVFKKALKEF RQNIFSFYSS ALAMDDGKSI
1921 RYKDLYALFE QILEKTMRLE QRDSLGESPV RVWVNTFKVF LDEYMNEFKT SDCTATKVPK
1981 TERKKRRKKE TDLVEEHNGH IFKATQYSIP TYCEYCSSLI WIMDRASVCK LCKYACHKKC
2041 CLKTTAKCSK KYDPELSSRQ FGVELSRLTS EDRTVPLVVE KLINYIEMHG LYTEGIYRKS
2101 GSTNKIKELR QGLDTDAESV NLDDYNIHVI ASVFKQWLRD LPNPLMTFEL YEEFLRAMGL
2161 QERKETIRGV YSVIDQLSRT HLNTLERLIF HLVRIALQED TNRMSANALA IVFAPCILRC
2221 PDTTDPLQSV QDISKTTTCV ELIVVEQMNK YKARLKDISS LEFAENKAKT RLSLIRRSMG
2281 KGRIRRGNYP GPSSPVVVRL PSVSDVSEET LTSEAAMETD ITEQQQAAMQ QEERVLTEQI
2341 ENLQKEKEEL TFEMLVLEPR ASDDETLESE ASIGTADSSE NLNMESEYAI SEKSERSLAL
2401 SSLKTAGKSE PSSKLRKQLK KQQDSLDVVD SSVSSLCLSN TASSHGTRKL FQIYSKSPFY
2461 RAASGNEALG MEGPLGQTKF LEDKPQFISR GTFNPEKGKQ KLKNVKNSPQ KTKETPEGTV
2521 MSGRRKTVDP DCTSNQQLAL FGNNEFMVLocalizationUniProt · AlphaFold · HPA
Whether an antibody against MYO9A can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 1
- Mean surface accessibility (rSASA)
- 0.44
- Highest tissue expression
- 57 nTPM
Expression across tissuesHPA
Tissue
- retina: 57 nTPM
- testis: 27 nTPM
- tongue: 14 nTPM
- kidney: 13 nTPM
- thyroid gland: 12 nTPM
- breast: 10 nTPM
Single-cell type
- rod photoreceptor cells: 1,298 nCPM
- loop of henle epithelial cells: 762 nCPM
- kupffer cells: 714 nCPM
- sertoli cells: 647 nCPM
- myonuclei: 614 nCPM
- proximal tubule cells: 606 nCPM
Immune cell
- plasmacytoid DC: 6.3 nTPM
- MAIT T-cell: 4.9 nTPM
- naive B-cell: 4.1 nTPM
- eosinophil: 3.8 nTPM
- gdT-cell: 3.6 nTPM
- naive CD4 T-cell: 3.6 nTPM
Brain region
- basal ganglia: 54 nTPM
- cerebellum: 52 nTPM
- cerebral cortex: 50 nTPM
- white matter: 49 nTPM
- amygdala: 45 nTPM
- thalamus: 43 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about MYO9A.
Disease | AllUniProt
Conditions MYO9A is implicated in, by any mechanism.
- Myasthenic syndrome, congenital, 24, presynaptic (CMS24) MIM:618198
Disease | GeneticClinVar
2 pathogenic / likely-pathogenic of 555 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Myasthenic syndrome, congenital, 24, presynaptic
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.3
- gnomAD pLI
- 0.49
- gnomAD missense Z
- 1.74
- DepMap mean gene effect
- -0.03
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- cell junction assembly
- establishment of epithelial cell apical/basal polarity
- intracellular signal transduction
- regulation of neuron projection arborization
- regulation of small GTPase mediated signal transduction
- visual perception
Molecular functions
- actin filament binding
- ATP binding
- GTPase activator activity
- microfilament motor activity
- zinc ion binding
Cellular components
Protein domainsUniProt · Pfam · InterPro
- IQ motif, EF-hand binding site
- Ras-associating domain
- Rho GTPase-activating protein domain
- Myosin head, motor domain-like
- Protein kinase C-like, phorbol ester/diacylglycerol-binding domain
- Rho GTPase activation protein
- P-loop containing nucleoside triphosphate hydrolase
- Ubiquitin-like domain superfamily
- Class IX myosin, motor domain
- Kinesin motor domain superfamily
- C1-like domain superfamily
- Unconventional class IX myosin
- Myosin head (motor domain)
- Phorbol esters/diacylglycerol binding domain (C1 domain)
- IQ calmodulin-binding motif
- RhoGAP domain
- Ras association (RalGDS/AF-6) domain
- Unconventional myosin-IXa, Ras-associating domain
- Unconventional myosin-IXa, Rho-GAP domain
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of MYO9A in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads MYO9A as an antibody target. Whether an autoantibody or antibody against MYO9A could matter depends on whether native MYO9A is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
MYO9A is annotated at the cell surface, where native MYO9A is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label MYO9A as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...